These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18715160)

  • 1. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients.
    Kumar D; Chen MH; Wong G; Cobos I; Welsh B; Siegal D; Humar A
    Clin Infect Dis; 2008 Oct; 47(7):885-92. PubMed ID: 18715160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients.
    Kumar D; Chen MH; Welsh B; Siegal D; Cobos I; Messner HA; Lipton J; Humar A
    Clin Infect Dis; 2007 Dec; 45(12):1576-82. PubMed ID: 18190318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients.
    Kumar D; Rotstein C; Miyata G; Arlen D; Humar A
    J Infect Dis; 2003 May; 187(10):1639-45. PubMed ID: 12721944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; Camara Rde L; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Bonnet E; Einsele H; Niederwieser D; Apperley J; Ljungman P
    Vaccine; 2010 Mar; 28(15):2730-4. PubMed ID: 20117269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
    Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
    Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
    Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
    Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
    Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity.
    Barton M; Wasfy S; Dipchand AI; Hébert D; Ng V; Solomon M; Fecteau A; Stephen D; Allen U
    Pediatr Infect Dis J; 2009 Aug; 28(8):688-92. PubMed ID: 19633514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.
    Nived P; Jönsson G; Settergren B; Einarsson J; Olofsson T; Jørgensen CS; Skattum L; Kapetanovic MC
    Arthritis Res Ther; 2020 Feb; 22(1):36. PubMed ID: 32087733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.
    Tobudic S; Plunger V; Sunder-Plassmann G; Riegersperger M; Burgmann H
    PLoS One; 2012; 7(9):e46133. PubMed ID: 23029408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
    Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
    Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, controlled trial comparing the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in adult liver transplant recipients.
    Eriksson M; Käyhty H; Lahdenkari M; Mäkisalo H; Anttila VJ
    Vaccine; 2021 Apr; 39(17):2351-2359. PubMed ID: 33812743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants.
    Gattringer R; Winkler H; Roedler S; Jaksch P; Herkner H; Burgmann H
    Transpl Infect Dis; 2011 Oct; 13(5):540-4. PubMed ID: 21489090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.